Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 12c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Catalyst Pharmaceutical Partners (CPRX) PT Lowered to $4.50 at Roth Capital
May 9, 2019 7:58 AM EDTRoth Capital analyst Scott Henry lowered the price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) to $4.50 (from $7.00) while maintaining a Buy rating.
... More